Tumor rejection antigens induced via epitope spreading

通过表位扩散诱导肿瘤排斥抗原

基本信息

  • 批准号:
    6725807
  • 负责人:
  • 金额:
    $ 10.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至 2004-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Human tumors are immunogenic and many tumor antigens have been identified. A problem now facing tumor immunologists is to determine what antigens are relevant to the destruction of tumor tissue, i.e. tumor rejection antigens. Ideal tumor rejection antigens would be ones that [1] are essential to the underlying biology of the tumor, [2] are the targets of a multifaceted immune response of high magnitude consisting of T helper cells, cytolytic T cells, and antibodies, and, [3] those to which an immune response confers therapeutic benefit. Previous studies from our laboratory have shown that stage IV breast cancer patients can be successfully immunized with HER-2/neu (HER2) peptide vaccines resulting in epitope spreading and improved survival. Both intramolecular and intermolecular epitope spreading occurred as a result of immunization. In autoimmune disease, epitope spreading is associated with aggressive tissue specific destruction. Epitope spreading may explain why our patients had improved survival. Identifying those antigens to which epitope spreading occurred in this population of stage IV breast cancer patients may prove useful in developing cancer vaccine strategies to target and specifically destroy tumor tissue. Our hypothesis is that these antigens may be tumor rejection antigens. The specific aims of this proposal are to: (1) identify potential "tumor rejection" antigens using sera derived from breast cancer patients immunized with a HER2 peptide-based vaccine who demonstrated epitope spreading and prolonged survival after active immunization, and, (2) determine whether antigens, identified through serologic screening, can be recognized by T cells derived from breast cancer patients. We will use the technique of serological analysis of recombinant cDNA expression libraries or "SEREX" to screen for tumor-specific antigens that were the result of epitope spreading following immunization. Many of the tumor specific IgG antibody responses identified in this fashion are high titer implying recognition by CD4+ T helper cells. Thus, it is assumed that antigens discovered using antibody immunity as a screening tool can be considered to be recognized by the CD4+ T helper cell repertoire (2) and, potentially, CTL. We will use post-immunization sera derived from Stage IV breast cancer patients that had both improved survival and epitope spreading following immunization with a HER2 peptide vaccine to identify novel immunogenic proteins. New antigens induced by immunization will be identified by "subtraction" of antigens recognized by the pre-vaccine serum. Subsequent studies will determine whether these new antigens, identified via serologic screening, can serve as T cell targets. Our goal is to develop immune-based strategies (e.g. vaccines) that would be associated with tumor destruction and survival benefit.
描述(申请人提供):人类肿瘤具有免疫原性,已鉴定出许多肿瘤抗原。肿瘤免疫学家目前面临的一个问题是确定哪些抗原与肿瘤组织的破坏有关,即肿瘤排斥抗原。理想的肿瘤排斥抗原应该是那些[1]对肿瘤的基本生物学至关重要的抗原,[2]是由T辅助细胞、细胞溶解T细胞和抗体组成的多方面免疫反应的目标,以及[3]那些免疫反应带来治疗益处的抗原。我们实验室以前的研究表明,HER-2/neu(HER2)多肽疫苗可以成功地免疫IV期乳腺癌患者,从而扩大表位,提高生存率。免疫导致分子内和分子间表位扩散。在自身免疫性疾病中,表位扩散与侵袭性组织特异性破坏有关。表位的传播可能解释了为什么我们的患者提高了存活率。在这群IV期乳腺癌患者中识别那些发生表位扩散的抗原,可能会被证明对开发癌症疫苗策略有帮助,以靶向并特异性地摧毁肿瘤组织。我们的假设是,这些抗原可能是肿瘤排斥抗原。这项建议的具体目的是:(1)使用以HER2多肽为基础的疫苗免疫的乳腺癌患者的血清,识别潜在的“肿瘤排斥”抗原,这些患者在主动免疫后表现出表位扩散和延长生存期,以及(2)确定通过血清学筛选鉴定的抗原是否能被乳腺癌患者的T细胞识别。 我们将使用重组cDNA表达文库的血清学分析技术或“SEREX”技术来筛选肿瘤特异性抗原,这些抗原是免疫后表位扩散的结果。以这种方式鉴定的许多肿瘤特异性抗体反应都是高滴度的,暗示着CD4+T辅助细胞的识别。因此,假设使用抗体免疫作为筛选工具发现的抗原可以被认为是被CD4+T辅助细胞库(2)识别的,并有可能被CTL识别。我们将使用来自IV期乳腺癌患者的免疫后血清,这些患者在接种HER2多肽疫苗后,既改善了生存率,又扩大了表位分布,以识别新的免疫原性蛋白。免疫诱导的新抗原将通过对疫苗前血清识别的抗原进行减法识别。随后的研究将确定这些通过血清学筛选鉴定的新抗原是否可以作为T细胞靶点。我们的目标是开发基于免疫的策略(例如疫苗),这些策略将与肿瘤破坏和生存益处相关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Keith L. Knutson其他文献

T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia
利用飞行时间质谱流式细胞技术(CyTOF)进行的T细胞免疫聚类分析确定了急性髓系白血病患者的独特亚组
  • DOI:
    10.1182/bloodadvances.2024014553
  • 发表时间:
    2025-01-28
  • 期刊:
  • 影响因子:
    7.100
  • 作者:
    Talha Badar;Keith L. Knutson;James Foran;Naseema Gangat;Kevin D. Pavelko;Scott H. Kaufmann;Mark R. Litzow;Hemant Murthy;Davitte Cogen;Margaret Ushman;Arini Arsana;Aref Al-Kali;Hassan Alkhateeb;Ayalew Tefferi;Mrinal Patnaik;Mithun Shah
  • 通讯作者:
    Mithun Shah
Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”
  • DOI:
    10.1007/s10549-006-9163-6
  • 发表时间:
    2006-03-16
  • 期刊:
  • 影响因子:
    3.000
  • 作者:
    Masoud H. Manjili;Hilal Arnouk;Keith L. Knutson;Maciej Kmieciak;Mary L. Disis;John R. Subjeck;A. Latif Kazim
  • 通讯作者:
    A. Latif Kazim
RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer
  • DOI:
    10.1007/s10555-014-9540-2
  • 发表时间:
    2014-12-30
  • 期刊:
  • 影响因子:
    8.700
  • 作者:
    Keith L. Knutson;Lavakumar Karyampudi;Purushottam Lamichhane;Claudia Preston
  • 通讯作者:
    Claudia Preston
CD4 regulatory T cells in human cancer pathogenesis
  • DOI:
    10.1007/s00262-006-0194-y
  • 发表时间:
    2006-07-04
  • 期刊:
  • 影响因子:
    5.100
  • 作者:
    Keith L. Knutson;Mary L. Disis;Lupe G. Salazar
  • 通讯作者:
    Lupe G. Salazar

Keith L. Knutson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Keith L. Knutson', 18)}}的其他基金

Animal Models
动物模型
  • 批准号:
    7727454
  • 财政年份:
    2009
  • 资助金额:
    $ 10.22万
  • 项目类别:
Project 8 - TH17 Dendritic Cell Vaccine
项目8——TH17树突状细胞疫苗
  • 批准号:
    9333237
  • 财政年份:
    2009
  • 资助金额:
    $ 10.22万
  • 项目类别:
Project 8 - TH17 Dendritic Cell Vaccine
项目8——TH17树突状细胞疫苗
  • 批准号:
    9149472
  • 财政年份:
    2009
  • 资助金额:
    $ 10.22万
  • 项目类别:
Analysis of serum folate receptor and antibody level for ovarian cancer detection
卵巢癌检测血清叶酸受体及抗体水平分析
  • 批准号:
    7288266
  • 财政年份:
    2006
  • 资助金额:
    $ 10.22万
  • 项目类别:
Analysis of serum folate receptor and antibody level for ovarian cancer detection
卵巢癌检测血清叶酸受体及抗体水平分析
  • 批准号:
    7196223
  • 财政年份:
    2006
  • 资助金额:
    $ 10.22万
  • 项目类别:
HLA classl complex expression in breast cancer immunity
乳腺癌免疫中HLA classl复合物的表达
  • 批准号:
    7069061
  • 财政年份:
    2005
  • 资助金额:
    $ 10.22万
  • 项目类别:
HLA classl complex expression in breast cancer immunity
乳腺癌免疫中HLA classl复合物的表达
  • 批准号:
    7587413
  • 财政年份:
    2005
  • 资助金额:
    $ 10.22万
  • 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
  • 批准号:
    7414086
  • 财政年份:
    2005
  • 资助金额:
    $ 10.22万
  • 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
  • 批准号:
    7229604
  • 财政年份:
    2005
  • 资助金额:
    $ 10.22万
  • 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
  • 批准号:
    6906817
  • 财政年份:
    2005
  • 资助金额:
    $ 10.22万
  • 项目类别:

相似国自然基金

CD8+T细胞亚群在抗MDA5抗体阳性皮肌炎中的致病机制研究
  • 批准号:
    82371805
  • 批准年份:
    2023
  • 资助金额:
    45.00 万元
  • 项目类别:
    面上项目
沙眼衣原体pORF5蛋白功能及其与宿主细胞相互作用的研究
  • 批准号:
    30970165
  • 批准年份:
    2009
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
    Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
    Fellowship
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
    Fellowship
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.22万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了